Huang et al. set out to develop small molecule inhibitorsof RAD52 through use of a HTS.168 The hitcompounds from this screen were tested for RAD52 selectivity, especiallyover RAD51, and in BRCA1/2 positive and deficient pancreas, ovarian,and triple negative breast cancer cells. Here, RAD52 is linked to triple-negative breast carcinoma.